Neurosurgical Review

, Volume 34, Issue 3, pp 253–264 | Cite as

Cytokine networks in glioma

  • Kenichiro Iwami
  • Atsushi Natsume
  • Toshihiko Wakabayashi
Review

Abstract

Glioma is the most frequently occurring brain tumor, but the prognosis of patients with gliomas remains poor despite advances in surgery, radiotherapy, and chemotherapy. Therefore, great efforts have been made to develop improved therapeutic strategies. Cytokines are a heterogeneous group of soluble small polypeptides or glycoproteins that exert pleiotropic and redundant effects that promote the growth, differentiation, and activation of normal cells. Cytokines have either pro- or anti-inflammatory activity and immunosuppressive activity, depending on the microenvironment surrounding the tumor. The microenvironment consists of heterogeneous tumor cells, immune cells, and extracellular matrix. Modulation of the microenvironment by the tumor is essential for its growth and progress. Cytokine production acts as a means of communication in the tumor microenvironment. In this article, we review the cross-talk between cytokines in the tumor microenvironment and the cytokine therapies that have been used till date for glioma treatment.

Keywords

Glioma Cancer immunology Cytokine Gene therapy 

Notes

References

  1. 1.
    Aigner L, Bogdahn U (2008) TGF-beta in neural stem cells and in tumors of the central nervous system. Cell Tissue Res 331:225–241PubMedCrossRefGoogle Scholar
  2. 2.
    Barker CF, Billingham RE (1977) Immunologically privileged sites. Adv Immunol 25:1–54PubMedCrossRefGoogle Scholar
  3. 3.
    Boehm U, Klamp T, Groot M, Howard JC (1997) Cellular responses to interferon-gamma. Annu Rev Immunol 15:749–795PubMedCrossRefGoogle Scholar
  4. 4.
    Boethius J, Blomgren H, Collins VP, Greitz T, Strander H (1983) The effect of systemic human interferon-alpha administration to patients with glioblastoma multiforme. Acta Neurochir (Wien) 68:239–251CrossRefGoogle Scholar
  5. 5.
    Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK, Suri A, Balasubramaniam A, Nair S, Oliushine V, Parfenov V, Poverennova I, Zaaroor M, Jachimczak P, Ludwig S, Schmaus S, Heinrichs H, Schlingensiepen KH (2011) Targeted therapy for high-grade glioma with the TGF-{beta}2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol 13:132–142PubMedCrossRefGoogle Scholar
  6. 6.
    Borish LC, Steinke JW (2003) 2. Cytokines and chemokines. J Allergy Clin Immunol 111:S460–S475PubMedCrossRefGoogle Scholar
  7. 7.
    Boulay JL, Paul WE (1992) The interleukin-4-related lymphokines and their binding to hematopoietin receptors. J Biol Chem 267:20525–20528PubMedGoogle Scholar
  8. 8.
    Brandes AA, Scelzi E, Zampieri P, Rigon A, Rotilio A, Amista P, Berti F, Fiorentino MV (1997) Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas. Am J Clin Oncol 20:364–367PubMedCrossRefGoogle Scholar
  9. 9.
    Buckner JC, Brown LD, Kugler JW, Cascino TL, Krook JE, Mailliard JA, Kardinal CG, Tschetter LK, O’Fallon JR, Scheithauer BW (1995) Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma. J Neurosurg 82:430–435PubMedCrossRefGoogle Scholar
  10. 10.
    Cabrillat H, Galizzi JP, Djossou O, Arai N, Yokota T, Arai K, Banchereau J (1987) High affinity binding of human interleukin 4 to cell lines. Biochem Biophys Res Commun 149:995–1001PubMedCrossRefGoogle Scholar
  11. 11.
    Cai G, Kastelein RA, Hunter CA (1999) IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN-gamma when combined with IL-18. Eur J Immunol 29:2658–2665PubMedCrossRefGoogle Scholar
  12. 12.
    Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC (2006) CNS immune privilege: hiding in plain sight. Immunol Rev 213:48–65PubMedCrossRefGoogle Scholar
  13. 13.
    Chawla-Sarkar M, Leaman DW, Borden EC (2001) Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res 7:1821–1831PubMedGoogle Scholar
  14. 14.
    Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC (2003) Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8:237–249PubMedCrossRefGoogle Scholar
  15. 15.
    Chiocca EA, Smith KM, McKinney B, Palmer CA, Rosenfeld S, Lillehei K, Hamilton A, DeMasters BK, Judy K, Kirn D (2008) A phase I trial of Ad.hIFN-beta gene therapy for glioma. Mol Ther 16:618–626PubMedCrossRefGoogle Scholar
  16. 16.
    Colombo F, Barzon L, Franchin E, Pacenti M, Pinna V, Danieli D, Zanusso M, Palu G (2005) Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther 12:835–848PubMedCrossRefGoogle Scholar
  17. 17.
    Cserr HF, Knopf PM (1992) Cervical lymphatics, the blood–brain barrier and the immunoreactivity of the brain: a new view. Immunol Today 13:507–512PubMedCrossRefGoogle Scholar
  18. 18.
    Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK (1995) Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin Cancer Res 1:1253–1258PubMedGoogle Scholar
  19. 19.
    Della Bella S, Nicola S, Riva A, Biasin M, Clerici M, Villa ML (2004) Functional repertoire of dendritic cells generated in granulocyte macrophage-colony stimulating factor and interferon-alpha. J Leukoc Biol 75:106–116PubMedCrossRefGoogle Scholar
  20. 20.
    Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425:577–584PubMedCrossRefGoogle Scholar
  21. 21.
    Dillman RO, Wiemann M, Oldham RK, Soori G, Bury M, Hafer R, Church C, DePriest C (1995) Interferon alpha-2a and external beam radiotherapy in the initial management of patients with glioma: a pilot study of the National Biotherapy Study Group. Cancer Biother 10:265–271PubMedCrossRefGoogle Scholar
  22. 22.
    Dubost JJ, Rolhion C, Tchirkov A, Bertrand S, Chassagne J, Dosgilbert A, Verrelle P (2002) Interleukin-6-producing cells in a human glioblastoma cell line are not affected by ionizing radiation. J Neurooncol 56:29–34PubMedCrossRefGoogle Scholar
  23. 23.
    Ehtesham M, Samoto K, Kabos P, Acosta FL, Gutierrez MA, Black KL, Yu JS (2002) Treatment of intracranial glioma with in situ interferon-gamma and tumor necrosis factor-alpha gene transfer. Cancer Gene Ther 9:925–934PubMedCrossRefGoogle Scholar
  24. 24.
    Farkkila M, Jaaskelainen J, Kallio M, Blomstedt G, Raininko R, Virkkunen P, Paetau A, Sarelin H, Mantyla M (1994) Randomised, controlled study of intratumoral recombinant gamma-interferon treatment in newly diagnosed glioblastoma. Br J Cancer 70:138–141PubMedCrossRefGoogle Scholar
  25. 25.
    Fillatreau S, Gray D, Anderton SM (2008) Not always the bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol 8:391–397PubMedCrossRefGoogle Scholar
  26. 26.
    Fiorentino DF, Bond MW, Mosmann TR (1989) Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 170:2081–2095PubMedCrossRefGoogle Scholar
  27. 27.
    Foxwell BM, Woerly G, Ryffel B (1989) Identification of interleukin 4 receptor-associated proteins and expression of both high- and low-affinity binding on human lymphoid cells. Eur J Immunol 19:1637–1641PubMedCrossRefGoogle Scholar
  28. 28.
    Galizzi JP, Zuber CE, Harada N, Gorman DM, Djossou O, Kastelein R, Banchereau J, Howard M, Miyajima A (1990) Molecular cloning of a cDNA encoding the human interleukin 4 receptor. Int Immunol 2:669–675PubMedCrossRefGoogle Scholar
  29. 29.
    Gehrmann J, Matsumoto Y, Kreutzberg GW (1995) Microglia: intrinsic immuneffector cell of the brain. Brain Res Brain Res Rev 20:269–287PubMedCrossRefGoogle Scholar
  30. 30.
    George J, Banik NL, Ray SK (2009) Combination of hTERT knockdown and IFN-gamma treatment inhibited angiogenesis and tumor progression in glioblastoma. Clin Cancer Res 15:7186–7195PubMedCrossRefGoogle Scholar
  31. 31.
    Groux H, Bigler M, de Vries JE, Roncarolo MG (1998) Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J Immunol 160:3188–3193PubMedGoogle Scholar
  32. 32.
    Groves MD, Puduvalli VK, Gilbert MR, Levin VA, Conrad CA, Liu VH, Hunter K, Meyers C, Hess KR, Alfred Yung WK (2009) Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. Br J Cancer 101:615–620PubMedCrossRefGoogle Scholar
  33. 33.
    Haque A, Banik NL, Ray SK (2007) Emerging role of combination of all-trans retinoic acid and interferon-gamma as chemoimmunotherapy in the management of human glioblastoma. Neurochem Res 32:2203–2209PubMedCrossRefGoogle Scholar
  34. 34.
    Haque A, Das A, Hajiaghamohseni LM, Younger A, Banik NL, Ray SK (2007) Induction of apoptosis and immune response by all-trans retinoic acid plus interferon-gamma in human malignant glioblastoma T98G and U87MG cells. Cancer Immunol Immunother 56:615–625PubMedCrossRefGoogle Scholar
  35. 35.
    Hau P, Jachimczak P, Schlingensiepen R, Schulmeyer F, Jauch T, Steinbrecher A, Brawanski A, Proescholdt M, Schlaier J, Buchroithner J, Pichler J, Wurm G, Mehdorn M, Strege R, Schuierer G, Villarrubia V, Fellner F, Jansen O, Straube T, Nohria V, Goldbrunner M, Kunst M, Schmaus S, Stauder G, Bogdahn U, Schlingensiepen KH (2007) Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 17:201–212PubMedCrossRefGoogle Scholar
  36. 36.
    Hawrylowicz CM, O’Garra A (2005) Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat Rev Immunol 5:271–283PubMedCrossRefGoogle Scholar
  37. 37.
    Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, Pierz DM, Chen DK, Budzilovich GN, Ransohoff J (1995) Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 76:840–852PubMedCrossRefGoogle Scholar
  38. 38.
    Heo DS, Yoon SJ, Kim WS, Lee KH, Seol JG, Lee SG, Jung CW, Cho EK, Kim CW, Park MH, Sung MW, Kim KH, Bang YJ, Kim NK (1998) Locoregional response and increased natural killer activity after intratumoral injection of HLA-B7/beta2-microglobulin gene in patients with cancer. Hum Gene Ther 9:2031–2038PubMedCrossRefGoogle Scholar
  39. 39.
    Hirakawa K, Ueda S, Nakagawa Y, Suzuki K, Fukuma S, Kita M, Imanishi J, Kishida T (1983) Effect of human leukocyte interferon on malignant brain tumors. Cancer 51:1976–1981PubMedCrossRefGoogle Scholar
  40. 40.
    Hjelmeland MD, Hjelmeland AB, Sathornsumetee S, Reese ED, Herbstreith MH, Laping NJ, Friedman HS, Bigner DD, Wang XF, Rich JN (2004) SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther 3:737–745PubMedGoogle Scholar
  41. 41.
    Hoffmann TK, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson JT, Whiteside TL (2002) Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 8:2553–2562PubMedGoogle Scholar
  42. 42.
    Holladay FP, Heitz-Turner T, Bayer WL, Wood GW (1996) Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma. J Neurooncol 27:179–189PubMedCrossRefGoogle Scholar
  43. 43.
    Honda K, Sakaguchi S, Nakajima C, Watanabe A, Yanai H, Matsumoto M, Ohteki T, Kaisho T, Takaoka A, Akira S, Seya T, Taniguchi T (2003) Selective contribution of IFN-alpha/beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection. Proc Natl Acad Sci USA 100:10872–10877PubMedCrossRefGoogle Scholar
  44. 44.
    Hotfilder M, Knupfer H, Mohlenkamp G, Pennekamp P, Knupfers M, Van Gool S, Wolff JE (2000) Interferon-gamma increases IL-6 production in human glioblastoma cell lines. Anticancer Res 20:4445–4450PubMedGoogle Scholar
  45. 45.
    Hu S, Chao CC, Ehrlich LC, Sheng WS, Sutton RL, Rockswold GL, Peterson PK (1999) Inhibition of microglial cell RANTES production by IL-10 and TGF-beta. J Leukoc Biol 65:815–821PubMedGoogle Scholar
  46. 46.
    Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H (1994) Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961–965PubMedCrossRefGoogle Scholar
  47. 47.
    Huettner C, Paulus W, Roggendorf W (1995) Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am J Pathol 146:317–322PubMedGoogle Scholar
  48. 48.
    Isaacs A, Lindenmann J (1957) Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 147:258–267PubMedCrossRefGoogle Scholar
  49. 49.
    Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA (1986) Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial. Cancer Res 46:2101–2104PubMedGoogle Scholar
  50. 50.
    Jaffee EM, Pardoll DM (1997) Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines. Methods 12:143–153PubMedCrossRefGoogle Scholar
  51. 51.
    Jakowlew SB (2006) Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 25:435–457PubMedCrossRefGoogle Scholar
  52. 52.
    Joosten SA, Ottenhoff TH (2008) Human CD4 and CD8 regulatory T cells in infectious diseases and vaccination. Hum Immunol 69:760–770PubMedCrossRefGoogle Scholar
  53. 53.
    Kim R, Emi M, Tanabe K (2006) Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology 119:254–264PubMedCrossRefGoogle Scholar
  54. 54.
    Kioi M, Seetharam S, Puri RK (2008) Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin. Mol Cancer Ther 7:1579–1587PubMedCrossRefGoogle Scholar
  55. 55.
    Kjellman C, Olofsson SP, Hansson O, Von Schantz T, Lindvall M, Nilsson I, Salford LG, Sjogren HO, Widegren B (2000) Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. Int J Cancer 89:251–258PubMedCrossRefGoogle Scholar
  56. 56.
    Knight MJ, Riffkin CD, Muscat AM, Ashley DM, Hawkins CJ (2001) Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells. Oncogene 20:5789–5798PubMedCrossRefGoogle Scholar
  57. 57.
    Knupfer MM, Poppenborg H, Van Gool S, Domula M, Wolff JE (1997) Interferon-gamma inhibits proliferation and adhesion of T98G human malignant glioma cells in vitro. Klin Pädiatr 209:271–274PubMedCrossRefGoogle Scholar
  58. 58.
    Knupfer MM, Knupfer H, Van Gool S, Domula M, Wolff JE (2000) Interferon gamma inhibits proliferation and hyaluronic acid adhesion of human malignant glioma cells in vitro. Cytokine 12:409–412PubMedCrossRefGoogle Scholar
  59. 59.
    Knupfer MM, Knupfer H, Jendrossek V, Van Gool S, Wolff JE, Keller E (2001) Interferon-gamma inhibits growth and migration of A172 human glioblastoma cells. Anticancer Res 21:3989–3994PubMedGoogle Scholar
  60. 60.
    Kruse CA, Cepeda L, Owens B, Johnson SD, Stears J, Lillehei KO (1997) Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother 45:77–87PubMedCrossRefGoogle Scholar
  61. 61.
    Krushelnycky BW, Farr-Jones MA, Mielke B, McKean JD, Weir BK, Petruk KC (1991) Development of a large-animal human brain tumor xenograft model in immunosuppressed cats. Cancer Res 51:2430–2437PubMedGoogle Scholar
  62. 62.
    Kunwar S, Chang SM, Prados MD, Berger MS, Sampson JH, Croteau D, Sherman JW, Grahn AY, Shu VS, Dul JL, Husain SR, Joshi BH, Pedain C, Puri RK (2006) Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. Neurosurg Focus 20:E15PubMedGoogle Scholar
  63. 63.
    Le Bon A, Etchart N, Rossmann C, Ashton M, Hou S, Gewert D, Borrow P, Tough DF (2003) Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 4:1009–1015PubMedCrossRefGoogle Scholar
  64. 64.
    Letterio JJ, Roberts AB (1998) Regulation of immune responses by TGF-beta. Annu Rev Immunol 16:137–161PubMedCrossRefGoogle Scholar
  65. 65.
    Liu S, Yu Y, Zhang M, Wang W, Cao X (2001) The involvement of TNF-alpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells. J Immunol 166:5407–5415PubMedGoogle Scholar
  66. 66.
    Ljungberg B, Grankvist K, Rasmuson T (1997) Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer 33:1794–1798PubMedCrossRefGoogle Scholar
  67. 67.
    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109PubMedCrossRefGoogle Scholar
  68. 68.
    Massague J (1998) TGF-beta signal transduction. Annu Rev Biochem 67:753–791PubMedCrossRefGoogle Scholar
  69. 69.
    Matarrese P, Di Biase L, Santodonato L, Straface E, Mecchia M, Ascione B, Parmiani G, Belardelli F, Ferrantini M, Malorni W (2002) Type I interferon gene transfer sensitizes melanoma cells to apoptosis via a target activity on mitochondrial function. Am J Pathol 160:1507–1520PubMedCrossRefGoogle Scholar
  70. 70.
    McGeer PL, Itagaki S, McGeer EG (1988) Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol 76:550–557PubMedCrossRefGoogle Scholar
  71. 71.
    Medawar PB (1948) Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 29:58–69PubMedGoogle Scholar
  72. 72.
    Miettinen PJ, Ebner R, Lopez AR, Derynck R (1994) TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol 127:2021–2036PubMedCrossRefGoogle Scholar
  73. 73.
    Montoya M, Schiavoni G, Mattei F, Gresser I, Belardelli F, Borrow P, Tough DF (2002) Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 99:3263–3271PubMedCrossRefGoogle Scholar
  74. 74.
    Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Khan TA, Mosmann TR (1990) Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 248:1230–1234PubMedCrossRefGoogle Scholar
  75. 75.
    Moore KW, de Waal MR, Coffman RL, O’Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683–765PubMedCrossRefGoogle Scholar
  76. 76.
    Moqbel R, Ying S, Barkans J, Newman TM, Kimmitt P, Wakelin M, Taborda-Barata L, Meng Q, Corrigan CJ, Durham SR, Kay AB (1995) Identification of messenger RNA for IL-4 in human eosinophils with granule localization and release of the translated product. J Immunol 155:4939–4947PubMedGoogle Scholar
  77. 77.
    Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL (1986) Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136:2348–2357PubMedGoogle Scholar
  78. 78.
    Mut M, Sherman JH, Shaffrey ME, Schiff D (2008) Cintredekin besudotox in treatment of malignant glioma. Expert Opin Biol Ther 8:805–812PubMedCrossRefGoogle Scholar
  79. 79.
    Nagai M, Arai T (1984) Clinical effect of interferon in malignant brain tumours. Neurosurg Rev 7:55–64PubMedCrossRefGoogle Scholar
  80. 80.
    Nakagawa Y, Hirakawa K, Ueda S, Suzuki K, Fukuma S, Kishida T, Imanishi J, Amagai T (1983) Local administration of interferon for malignant brain tumors. Cancer Treat Rep 67:833–835PubMedGoogle Scholar
  81. 81.
    Nakahara N, Pollack IF, Storkus WJ, Wakabayashi T, Yoshida J, Okada H (2003) Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells. Cancer Gene Ther 10:549–558PubMedCrossRefGoogle Scholar
  82. 82.
    Natsume A, Mizuno M, Ryuke Y, Yoshida J (1999) Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse. Gene Ther 6:1626–1633PubMedCrossRefGoogle Scholar
  83. 83.
    Natsume A, Tsujimura K, Mizuno M, Takahashi T, Yoshida J (2000) IFN-beta gene therapy induces systemic antitumor immunity against malignant glioma. J Neurooncol 47:117–124PubMedCrossRefGoogle Scholar
  84. 84.
    Natsume A, Ishii D, Wakabayashi T, Tsuno T, Hatano H, Mizuno M, Yoshida J (2005) IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res 65:7573–7579PubMedGoogle Scholar
  85. 85.
    Natsume A, Wakabayashi T, Ishii D, Maruta H, Fujii M, Shimato S, Ito M, Yoshida J (2008) A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation. Cancer Chemother Pharmacol 61:653–659PubMedCrossRefGoogle Scholar
  86. 86.
    Naumann U, Maass P, Gleske AK, Aulwurm S, Weller M, Eisele G (2008) Glioma gene therapy with soluble transforming growth factor-beta receptors II and III. Int J Oncol 33:759–765PubMedGoogle Scholar
  87. 87.
    O’Garra A, Vieira P (2007) T(H)1 cells control themselves by producing interleukin-10. Nat Rev Immunol 7:425–428PubMedCrossRefGoogle Scholar
  88. 88.
    O’Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowicz C (2008) Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev 223:114–131PubMedCrossRefGoogle Scholar
  89. 89.
    Okada H, Kuwashima N (2002) Gene therapy and biologic therapy with interleukin-4. Curr Gene Ther 2:437–450PubMedCrossRefGoogle Scholar
  90. 90.
    Okada H, Lieberman FS, Edington HD, Witham TF, Wargo MJ, Cai Q, Elder EH, Whiteside TL, Schold SC Jr, Pollack IF (2003) Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. J Neurooncol 64:13–20PubMedGoogle Scholar
  91. 91.
    Park LS, Friend D, Sassenfeld HM, Urdal DL (1987) Characterization of the human B cell stimulatory factor 1 receptor. J Exp Med 166:476–488PubMedCrossRefGoogle Scholar
  92. 92.
    Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L (2007) Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 18:226–232PubMedCrossRefGoogle Scholar
  93. 93.
    Parney IF, Chang LJ, Farr-Jones MA, Hao C, Smylie M, Petruk KC (2006) Technical hurdles in a pilot clinical trial of combined B7-2 and GM-CSF immunogene therapy for glioblastomas and melanomas. J Neurooncol 78:71–80PubMedCrossRefGoogle Scholar
  94. 94.
    Pepper MS (1997) Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 8:21–43PubMedCrossRefGoogle Scholar
  95. 95.
    Phillips LM, Lampson LA (1999) Site-specific control of T cell traffic in the brain: T cell entry to brainstem vs. hippocampus after local injection of IFN-gamma. J Neuroimmunol 96:218–227PubMedCrossRefGoogle Scholar
  96. 96.
    Plaut M, Pierce JH, Watson CJ, Hanley-Hyde J, Nordan RP, Paul WE (1989) Mast cell lines produce lymphokines in response to cross-linkage of Fc epsilon RI or to calcium ionophores. Nature 339:64–67PubMedCrossRefGoogle Scholar
  97. 97.
    Rajkumar SV, Buckner JC, Schomberg PJ, Cascino TL, Burch PA, Dinapoli RP (1998) Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma. Int J Radiat Oncol Biol Phys 40:297–302PubMedCrossRefGoogle Scholar
  98. 98.
    Ronnov-Jessen L, Petersen OW (1993) Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab Invest 68:696–707PubMedGoogle Scholar
  99. 99.
    Roussel E, Gingras MC, Grimm EA, Bruner JM, Moser RP (1996) Predominance of a type 2 intratumoural immune response in fresh tumour-infiltrating lymphocytes from human gliomas. Clin Exp Immunol 105:344–352PubMedCrossRefGoogle Scholar
  100. 100.
    Rowbottom AW, Lepper MA, Garland RJ, Cox CV, Corley EG (1999) Interleukin-10-induced CD8 cell proliferation. Immunology 98:80–89PubMedCrossRefGoogle Scholar
  101. 101.
    Santin AD, Hermonat PL, Ravaggi A, Bellone S, Pecorelli S, Roman JJ, Parham GP, Cannon MJ (2000) Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes. J Virol 74:4729–4737PubMedCrossRefGoogle Scholar
  102. 102.
    Santini SM, Lapenta C, Logozzi M, Parlato S, Spada M, Di Pucchio T, Belardelli F (2000) Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 191:1777–1788PubMedCrossRefGoogle Scholar
  103. 103.
    Schiltz PM, Gomez GG, Read SB, Kulprathipanja NV, Kruse CA (2002) Effects of IFN-gamma and interleukin-1beta on major histocompatibility complex antigen and intercellular adhesion molecule-1 expression by 9L gliosarcoma: relevance to its cytolysis by alloreactive cytotoxic T lymphocytes. J Interferon Cytokine Res 22:1209–1216PubMedCrossRefGoogle Scholar
  104. 104.
    Schlingensiepen KH, Schlingensiepen R, Steinbrecher A, Hau P, Bogdahn U, Fischer-Blass B, Jachimczak P (2006) Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. Cytokine Growth Factor Rev 17:129–139PubMedCrossRefGoogle Scholar
  105. 105.
    Schneider T, Becker A, Ringe K, Reinhold A, Firsching R, Sabel BA (2008) Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles. J Neuroimmunol 195:21–27PubMedCrossRefGoogle Scholar
  106. 106.
    Segal BM, Glass DD, Shevach EM (2002) Cutting Edge: IL-10-producing CD4+ T cells mediate tumor rejection. J Immunol 168:1–4PubMedGoogle Scholar
  107. 107.
    Sidky YA, Borden EC (1987) Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 47:5155–5161PubMedGoogle Scholar
  108. 108.
    Sloan AE, Dansey R, Zamorano L, Barger G, Hamm C, Diaz F, Baynes R, Wood G (2000) Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Neurosurg Focus 9:e9PubMedCrossRefGoogle Scholar
  109. 109.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRefGoogle Scholar
  110. 110.
    Tada M, Diserens AC, Desbaillets I, de Tribolet N (1994) Analysis of cytokine receptor messenger RNA expression in human glioblastoma cells and normal astrocytes by reverse-transcription polymerase chain reaction. J Neurosurg 80:1063–1073PubMedCrossRefGoogle Scholar
  111. 111.
    Thyrell L, Erickson S, Zhivotovsky B, Pokrovskaja K, Sangfelt O, Castro J, Einhorn S, Grander D (2002) Mechanisms of interferon-alpha induced apoptosis in malignant cells. Oncogene 21:1251–1262PubMedCrossRefGoogle Scholar
  112. 112.
    Tran Thang NN, Derouazi M, Philippin G, Arcidiaco S, Di Berardino-Besson W, Masson F, Hoepner S, Riccadonna C, Burkhardt K, Guha A, Dietrich PY, Walker PR (2010) Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development. Cancer Res 70:4829–4839PubMedCrossRefGoogle Scholar
  113. 113.
    Tran TT, Uhl M, Ma JY, Janssen L, Sriram V, Aulwurm S, Kerr I, Lam A, Webb HK, Kapoun AM, Kizer DE, McEnroe G, Hart B, Axon J, Murphy A, Chakravarty S, Dugar S, Protter AA, Higgins LS, Wick W, Weller M, Wong DH (2007) Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model. Neuro Oncol 9:259–270PubMedCrossRefGoogle Scholar
  114. 114.
    Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, Murphy A, Wong DH, Wick W, Higgins LS, Weller M (2004) SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 64:7954–7961PubMedCrossRefGoogle Scholar
  115. 115.
    Vallieres L (2009) Trabedersen, a TGFbeta2-specific antisense oligonucleotide for the treatment of malignant gliomas and other tumors overexpressing TGFbeta2. IDrugs 12:445–453PubMedGoogle Scholar
  116. 116.
    Vaquero J, Martinez R (1992) Intratumoral immunotherapy with interferon-alpha and interleukin-2 in glioblastoma. Neuroreport 3:981–983PubMedCrossRefGoogle Scholar
  117. 117.
    Velazquez JR, Lacy P, Mahmudi-Azer S, Bablitz B, Milne CD, Denburg JA, Moqbel R (2000) Interleukin-4 and RANTES expression in maturing eosinophils derived from human cord blood CD34+ progenitors. Immunology 101:419–425PubMedCrossRefGoogle Scholar
  118. 118.
    Wakabayashi T, Hatano N, Kajita Y, Yoshida T, Mizuno M, Taniguchi K, Ohno T, Nagasaka T, Yoshida J (2000) Initial and maintenance combination treatment with interferon-beta, MCNU (Ranimustine), and radiotherapy for patients with previously untreated malignant glioma. J Neurooncol 49:57–62PubMedCrossRefGoogle Scholar
  119. 119.
    Wakabayashi T, Natsume A, Hashizume Y, Fujii M, Mizuno M, Yoshida J (2008) A phase I clinical trial of interferon-beta gene therapy for high-grade glioma: novel findings from gene expression profiling and autopsy. J Gene Med 10:329–339PubMedCrossRefGoogle Scholar
  120. 120.
    Watters JJ, Schartner JM, Badie B (2005) Microglia function in brain tumors. J Neurosci Res 81:447–455PubMedCrossRefGoogle Scholar
  121. 121.
    Weber F, Asher A, Bucholz R, Berger M, Prados M, Chang S, Bruce J, Hall W, Rainov NG, Westphal M, Warnick RE, Rand RW, Floeth F, Rommel F, Pan H, Hingorani VN, Puri RK (2003) Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 64:125–137PubMedGoogle Scholar
  122. 122.
    Williams LM, Ricchetti G, Sarma U, Smallie T, Foxwell BM (2004) Interleukin-10 suppression of myeloid cell activation—a continuing puzzle. Immunology 113:281–292PubMedCrossRefGoogle Scholar
  123. 123.
    Wintterle S, Schreiner B, Mitsdoerffer M, Schneider D, Chen L, Meyermann R, Weller M, Wiendl H (2003) Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res 63:7462–7467PubMedGoogle Scholar
  124. 124.
    Wolff JE, Wagner S, Reinert C, Gnekow A, Kortmann RD, Kuhl J, Van Gool SW (2006) Maintenance treatment with interferon-gamma and low-dose cyclophosphamide for pediatric high-grade glioma. J Neurooncol 79:315–321PubMedCrossRefGoogle Scholar
  125. 125.
    Wrann M, Bodmer S, de Martin R, Siepl C, Hofer-Warbinek R, Frei K, Hofer E, Fontana A (1987) T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta. EMBO J 6:1633–1636PubMedGoogle Scholar
  126. 126.
    Wu A, Wei J, Kong LY, Wang Y, Priebe W, Qiao W, Sawaya R, Heimberger AB (2010) Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol 12:1113–1125PubMedCrossRefGoogle Scholar
  127. 127.
    Wynn TA (2003) IL-13 effector functions. Annu Rev Immunol 21:425–456PubMedCrossRefGoogle Scholar
  128. 128.
    Yoshida J, Kajita Y, Wakabayashi T, Sugita K (1994) Long-term follow-up results of 175 patients with malignant glioma: importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation. Acta Neurochir (Wien) 127:55–59CrossRefGoogle Scholar
  129. 129.
    Yoshida J, Mizuno M, Fujii M, Kajita Y, Nakahara N, Hatano M, Saito R, Nobayashi M, Wakabayashi T (2004) Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon beta gene using cationic liposomes. Hum Gene Ther 15:77–86PubMedCrossRefGoogle Scholar
  130. 130.
    Yoshimoto T, Paul WE (1994) CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J Exp Med 179:1285–1295PubMedCrossRefGoogle Scholar
  131. 131.
    Zou JP, Morford LA, Chougnet C, Dix AR, Brooks AG, Torres N, Shuman JD, Coligan JE, Brooks WH, Roszman TL, Shearer GM (1999) Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. J Immunol 162:4882–4892PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Kenichiro Iwami
    • 1
  • Atsushi Natsume
    • 1
  • Toshihiko Wakabayashi
    • 1
  1. 1.Department of NeurosurgeryNagoya University School of MedicineNagoyaJapan

Personalised recommendations